Therefore, among the included gliomas, Nrf2 expression scores in WHO grade III and IV tumors were significantly higher than those in WHO grade I and II tumors (p = 1.3 × 10−5, Figure 5A). This evidence concerns the gene NFE2L2 and central nervous system cancer.